GBtherapeutics Ltd.
This article was originally published in Start Up
Executive Summary
GBtherapeutics Ltd. has amassed a large library of nitric oxide mimetics that selectively target brain tissue. The Canadian start-up believes that these compounds, which operate through multiple mechanisms not fully characterized, present new ways to combat age-related declines in cognition and memory.